Boundless Bio, Inc.

NASDAQ:BOLD

Biotechnology

Healthcare
$2.40 +85.71%

+$1.20 today

Market cap
$56.67M
Beta
0.97
P/E (TTM)
-1.0
EPS (TTM)
-$2.50
52W Low $0.96High $2.75

Volume 0.15M

Average 0.22M

BOLD Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Boundless Bio, Inc.NASDAQ: BOLD

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$273.22M, compared with -$217.23M a year earlier.

Context

  • Retained earnings amounted to 193.8% of total assets at the end of Q1 FY2026, up 80.2 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -25.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$273.22M-5.2% QoQ
Last fiscal yearDec 2025
-$259.67M-28.9% YoY
Year agoMar 2025
-$217.23M-25.8% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.8%——
1 year-28.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(259.67M) USD
Year-over-year change
-28.9%

Retained Earnings vs competitors

How BOLD compares with its peers on the latest reported figures

  • BOLD's Mar 2026 retained earnings of -$273.22M is the 3rd highest of the 4 companies compared; the peer median is -$250.98M.
  • Its year-over-year change of -25.8% is the lowest of 4, against a peer median of -2.6%.
  • Retained earnings amounts to 193.8% of total assets for BOLD, versus a peer median of 333.9%.
BOLD Competitors Peer median
Retained Earnings for BOLD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
QTTBQ32 Bio Inc.Mar 2026-$212.6M +13.5%—333.9%
ANTXAN2 Therapeutics, Inc.Mar 2026-$250.98M -16.0%—286.9%
BOLDBoundless Bio, Inc.Mar 2026-$273.22M -25.8%—193.8%
RLYBRallybio CorporationMar 2026-$310.28M -2.6%—569.6%
Peer median (excluding BOLD) -$250.98M-2.6%—333.9%

Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents34.29M10.95M23.71M26.59M17.87M
Short-term Investments38.74M55.77M97.05M125.53M89.71M
Net Receivables00000
Inventory00000
Other Current Assets1.54M1.32M3.45M2.28M2.03M
Total Current Assets74.57M68.04M124.2M154.39M109.61M
Property, Plant & Equipment (Net)3.1M7.73M4.58M51.36M46.88M
Goodwill00000
Intangible Assets00000
Long-term Investments34.99M0560K00
Tax Assets00000
Other Non-current Assets1.07M1.07M555K659K573K
Total Non-current Assets39.15M8.79M5.69M52.02M47.45M
Total Assets113.72M76.83M129.89M206.41M157.06M
Account Payables1.08M1.4M2.22M1.27M1.49M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.51M2.55M2.9M2.78M2.64M
Total Current Liabilities3.87M7.73M9.36M8.14M12.54M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities148.04M147.95M247.62M00
Total Non-current Liabilities148.04M150.8M247.62M47.63M45.87M
Total Liabilities151.91M158.53M256.98M55.77M58.41M
Common Stock2K2K02K2K
Retained Earnings(40.77M)(86.68M)(136.11M)(201.47M)(259.67M)
Accumulated OCI(175K)(398K)40K121K64K
Other Stockholders Equity002K00
Minority Interest00000
Total Equity(38.19M)(81.7M)(127.08M)150.64M98.65M
Total Debt377K5.18M2.2M47.63M49.04M
Net Debt(33.91M)(5.77M)(21.51M)21.05M31.17M

Boundless Bio, Inc.

NASDAQ:BOLD

Intrinsic Alpha fair value

Locked

Current Price

$2.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.